POLYPEPTIDE FOR BLOOD SUGAR LEVEL REDUCING ON BASIS OF HUMAN GLUCAGON-LIKE PEPTIDE-1, RECOMBINANT PRODUCING STRAIN E. COLI AND METHOD OF OBTAINING THIS POLYPEPTIDE Russian patent published in 2018 - IPC C07K14/605 C12N1/21 C12P21/02 C12R1/19 

FIELD: biotechnology.

SUBSTANCE: recombinant modified human glucagon-like peptide-1 (rmGLP-1), a method for its preparation, and strain E.coli RNCIM B-12555 are proposed. rmGLP-1 has the sequence of SEQ ID NO 1. rmGLP-1 is produced by culturing a recombinant strain E. coli RNCIM B-12555 to prepare the rmGLP-1 peptide precursor, then isolating the resulting precursor, its autocatalytic cleavage and purification of the target polypeptide. The mouse model shows that with subcutaneous or intramuscular administration, rmGLP-1 has indicators of sugar reduction activity and duration of action similar to that of the commercial preparation "Lysxemia" obtained using chemical synthesis and, for a minimum of 3 hours after administration, is able to effectively reduce the level of glucose in blood almost twice as compared with the control.

EFFECT: abovementioned strain allows biosynthesis of the precursor rmGLP-1 at 40 percent of the total protein of the cells, which corresponds to the biosynthesis of rmGLP-1 at 13 percent of the total cell protein.

3 cl, 3 dwg, 7 ex